Neurizon Therapeutics Ltd: Appendix 4D - Half-year Financial Report - 31 December 2024

ASXFeb 16 22:28 ET · Announcements

Neurizon Gets US Patent for Cancer Drug Candidate; Shares Up 16%

MT NewswiresFeb 4 23:00 ET

Neurizon Therapeutics Says FDA Places Its Investigational New Drug Application on Hold; Shares Hit New 52-Week Low

MT NewswiresJan 16 20:18 ET

Neurizon's ALS Drug Candidate Receives Orphan Medicinal Product Designation in Europe; Shares Down 3%

MT NewswiresDec 17, 2024 21:41 ET

Neurizon Reports Positive Results From Preclinical Study of Amyotrophic Lateral Sclerosis Treatment Candidate; Shares Fall 4%

MT NewswiresNov 17, 2024 23:34 ET

Neurizon's Fast-track Application for Flagship Drug in Europe Received 'Positively'

The Market HeraldNov 10, 2024 18:54 ET